Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.
|
31471312 |
2019 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Our results reveal an epigenetic block to differentiation in CC-ICs and demonstrate the potential for epigenetic differentiation therapy of a solid tumour through EZH2 inhibition.
|
30926792 |
2019 |
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Clinical research evaluating BET and EZH2 inhibitors is still at an early stage; however, both classes of drugs have demonstrated activity among different hematologic malignancies and solid tumors.
|
30715616 |
2019 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In preclinical models encompassing a broad spectrum of EZH2-aberrant solid tumors, a combination of EZH2 and BRD4 inhibitors, or a triple-combination including MAPK inhibition display robust efficacy with very tolerable toxicity.
|
30220457 |
2018 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Three EZH2 inhibitors: tazemetostat (EPZ-6438), GSK2816126 and CPI-1205 have moved into phase I/phase II clinical trials in patients with non-Hodgkin lymphoma and genetically defined solid tumors.
|
29473431 |
2018 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Pharmacological EZH2 inhibitors are currently in clinical trials for the treatment of B-cell lymphomas and solid tumors.
|
26411517 |
2016 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These emerging data suggest that EZH2 inhibitors represent a very promising class of drugs, which will probably have a major impact on improving outcome and reducing toxicity for patients with indolent and aggressive B-cell lymphomas and other specific solid tumors.
|
27179746 |
2016 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In contrast, we recently showed that EZH2 is dispensable for solid tumor development and that its elevated expression reflects the abnormally high proliferation rate of cancer cells.
|
27419533 |
2016 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Our study provides an unexpected understanding of EZH2's contribution to solid tumors with important therapeutic implications.
|
26637281 |
2015 |
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of EZH2 is a marker of advanced and metastatic disease in many solid tumors, including prostate and breast cancer.
|
21367748 |
2011 |
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of EZH2 has been found in several human malignancies including hematological and solid tumors.
|
21289264 |
2011 |
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder.
|
18806826 |
2008 |
Solid Neoplasm
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear.
|
19008416 |
2008 |
Solid Neoplasm
|
0.400 |
CausalMutation
|
phenotype |
CGI |
|
|
|